Research and Markets has announced the addition of the "Rectal Cancer - Pipeline Review, H2 2016" report to their offering.
Rectal Cancer pipeline therapeutics constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies.The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 5, 3 and 1 respectively.
Rectal Cancer - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Rectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/4qld8n/rectal_cancer
Related Topics: Colon Cancer Drugs
View source version on businesswire.com: http://www.businesswire.com/news/home/20160920005817/en/Business Wire
Last updated on: 20/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.